Skip to main content

Advertisement

SpringerLink
Log in

Intracerebral chemotherapy in the 9L rat brain tumor model

  • Laboratory Investigation
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Summary

We have used the 9L rat brain tumor model to search for effective chemotherapeutic approaches to the management of brain tumors. Several antineoplastic agents which have been proposed or are currently being used for human brain tumors, including 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU), bleomycin, aziridinylbenzoquinone (AZQ), cis-Platinum, and acivicin, were administered intravenously (iv), intraperitoneally (ip), or intracerebrally (ic) to rats burdened with the intracranial 9L gliosarcoma. The results confirm that BCNU is the most effective systemic agent among the chemotherapeutic agents tested as indicated by its ability to significantly increase the median survival time (MST) and life span of the tumor-burdened animals. Bleomycin is an effective agent against the intracranial 9L tumor when administered ic. While neither systemic single iv dose AZQ (0.5–2.5 mg/kg) nor multiple ip treatments (0.5–1.0 mg/kg × 5, q 6 h) were effective in prolonging the survival, single is dose AZQ (5–50 μg/rat) treatment significantly increased the MST of the treated animals (P < 0.05). Systemic AZQ treatments using higher doses produced a hematological toxicity, resulting in a decrease in MST of the treated animals. Cis-Platinum, either administered ip or ic, produced only a marginal effect on survival, although acute neurologic toxicity limited the dose of cis-Patinum that could be administered ic. Acivicin, either administered ip or ic, produced no effect on the survival of treated animals. Our results suggest that local treatment with certain antineoplastic agents may be an efficient therapy in the management of brain tumors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Kornblith PL, Walker N: Chemotherapy for malignant gliomas. J Neurosurg 68: 1–17, 1988

    Google Scholar 

  2. Blasberg RG, Patlak C, Fenstermacher JD: Intrathecal chemotherapy: Brain tissue profiles after ventriculocisternal perfusion. J Pharmacol Exp Ther 195: 73–83, 1975

    Google Scholar 

  3. Blasberg RG, Patlak CS, Shapiro WR: Distribution of methotrexate in the cerebrospinal fluid and brain after intraventricular administration. Cancer Treat Rep 61: 633–641, 1977

    Google Scholar 

  4. Shapiro WR, Green SB: Reevaluating the efficacy of intra-arterial BCNU. J Neurosurg 66: 313–315, 1987

    Google Scholar 

  5. Fenn LG, Wallace S, Stewart DJ, Chuang VP, Yung WKA, Leavens ME, Burgess MA, Savaraj N, Benjamin RS, Young SE, Tang RA, Handel S, Mavligit G, Fields WS: Intracarotid infusion of cis-diaminedichloroplatinum in the treatment of recurrent malignant brain tumors. Cancer 54: 794–799, 1984

    Google Scholar 

  6. Tator CH: Intraneoplastic injection of CCNU for experimental brain tumor chemotherapy. Surg Neurol 7: 73–77, 1977

    Google Scholar 

  7. Tomita T: Interstitial chemotherapy for brain tumors: review. J Neuro-Oncol 10: 57–74, 1991

    Google Scholar 

  8. Weiss SR, Raskind R: Treatment of malignant brain tumors by local methotrexate: a preliminary report. Int Surg 51:149–155, 1969

    Google Scholar 

  9. Garfield J, Dayan AD: Postoperative intracavity chemotherapy of malignant gliomas, preliminary study using methotrexate. J Neurosurg 39: 315–322, 1975

    Google Scholar 

  10. Bouvier G, Penn RD, Kroin JS, Beique R, Guerard MJ: Direct delivering of medication into a brain tumor through multiple chronically implanted catheters. Neurosurgery 20: 286–291, 1987

    Google Scholar 

  11. Vats TS, Morantz RA, Wood GW, Tilzer S: Study of effectiveness of bleomycin in rat brain tumor model intravenously and intracerebrally. Int J Radiat Oncol Biol Phys 5: 1527–1529, 1979

    Google Scholar 

  12. Kimler BF, Vats TS, Morantz RA, Henderson SD: Response of the 9L rat brain tumor to combination treatment with radiation and bleomycin. Int J Radiat Oncol Biol Phys 7:1069–1074, 1981

    Google Scholar 

  13. Kimler BF, Martin DF, Evans RG, Morantz RA, Vats TS: Combination of radiation therapy and intracranial bleomycin in the 9L rat brain tumor model. Int J Radiat Oncol Biol Phys 18: 1115–1121, 1990

    Google Scholar 

  14. Morantz RA, Kimler BF, Vats TS, Henderson SD: Bleomycin and brain tumors: a review. J Neuro-Oncol 1: 249–255, 1983

    Google Scholar 

  15. Stewart DJ, O'Bryan RM, Al-Sarraf M: Phase II study of cisplatin in recurrent astrocytomas in adults: A Southwest Oncology Group study. J Neuro-Oncol 1: 145–147, 1983

    Google Scholar 

  16. Eagan RT, Dinapoli RP, Cascino TL, Scheithauer B, O'Neil BP, O'Fallon JR: Comprehensive phase II evaluation of aziridinylbenzoquinone (AZQ, Diaziquone) in recurrent human primary brain tumors. J Neuro-Oncol 5: 309–314, 1987

    Google Scholar 

  17. Ettinger LJ, Ru N, Krailo M, Ruccione KS, Krivit W, Hammond GD: A phase II study of diaziquone in children with recurrent or progressive primary brain tumors: A report from the Childrens Cancer Study Group. J Neuro-Oncol 9: 69–76, 1990

    Google Scholar 

  18. Taylor SA, Crowley J, Pollock TW, Eyre HJ, Jaeckle C, Hynes HE, Stephens RL: Objective antitumor activity of acivicin in patients with recurrent CNS malignancies: A Southwest Oncology Group Trial. J Clin Oncol 9: 1476–1479, 1991

    Google Scholar 

  19. Henderson SD, Kimler BF, Morantz RA: Radiation therapy of 9L rat brain tumors. Int J Radiat Oncol Biol Phys 7: 497–502, 1981

    Google Scholar 

  20. Zar JH: Biostatistical Analysis. Prentice-Hall, Inc., Englewood Cliffs, NJ, 130–161, 1974

    Google Scholar 

  21. Gehan EA: A generalized Wilcoxon test for comparing arbitrarily singly-censored samples. Biometrika 52: 203–223 1965

    Google Scholar 

  22. Barker M, Deen DF, Barker DG: BCNU and X-ray therapy of intracerebral 9L rat tumor. Int J Radiat Oncol Biol Phys 5: 1581–1583, 1979

    Google Scholar 

  23. Wheeler KT, Kaufman K, Feldstein M: Influence of fractionation schedules on the response of a rat brain tumor to therapy with BCNU and radiation. Int J Radiat Oncol Biol Phys 6: 845–849, 1980

    Google Scholar 

  24. Walker MD, Alexander E Jr, Hunt WE, MacCarty CS, Mahaley MS Jr, Mealey J Jr, Norrell HA, Owens G, Ransohoff J, Wilson CB, Gehan EA, Strike TA: Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg 49: 333–343, 1978

    Google Scholar 

  25. Nelson DF, Schoenfeld D, Weinstein AS, Nelson JS, Wasserman T, Goodman RL, Carabell S: A randomized comparison of misonidazole sensitized radiotherapy plus BCNU for treatment of malignant glioma after surgery; preliminary results of an RTOG study. Int J Radiat Oncol Biol Phys 9: 1143–1151, 1983

    Google Scholar 

  26. Khan AH, Driscoll JS: Potential central nervous system antitumor agents. Aziridinylbenzoquinones. 1. J Med Chem 19: 313–317, 1976

    Google Scholar 

  27. Chou FT, Khan AH, Driscoll JS: Potential central nervous system antitumor agents. Aziridinylbenzoquinones. 2. J Med Chem 19: 1302–1308, 1976

    Google Scholar 

  28. Schold SC Jr, Rawlings CE, Bigner SH, Bigner DD: Intracerebral growth of a human glioma tumor line in athymic mice and treatment with procarbazine, 1,3-bis (2-chloroethyl)-1-nitrosourea, aziridinylbenzoquinone, and cisplatinum. Neurosurgery 12: 672–677, 1983

    Google Scholar 

  29. Schold SC Jr, Friedman HS, Bjornsson TD: Treatment of human glioma and medulloblastoma tumor lines in athymic mice with diaziquone-based drug combinations. Cancer Res 44: 2352–2357, 1984

    Google Scholar 

  30. Greenberg HS, Ensminger WD, Layton PB, Gebarski S, Meyer M, Chaffee B, Bender JF, Grillo-Lopez AJ: Phase I-II evaluation of intra-arterial diaziquone for recurrent malignant astrocytomas. Cancer Treat Rep 70: 353–357, 1986

    Google Scholar 

  31. Falletta JM, Cushing B, Lauer S, Bell B, Mahoney DH, Castleberry R, Krance RA: Phase I evaluation of diaziquone in childhood cancer. Invest New Drugs 8:167–170, 1990

    Google Scholar 

  32. Schold SC Jr, Mahaley MS Jr, Vick NA, Friedman HS, Burger PC, Delong ER, Albrig RE Jr, Bullard DE, Khander JD, Cairncross JG, MacDonald DR, Falletta JM: Phase II diaziquone-based chemotherapy trials in patients with anaplastic supratentorial astrocytic neoplasms. J Clin Oncol 5: 464–471, 1987

    Google Scholar 

  33. Loehrer PJ, Einhorn LH: Drugs five years later: cisplatin. Ann Intern Med 100: 704–713, 1984

    Google Scholar 

  34. Henderson SD, Kimler BF, Barnes ML: Comparison of cancer chemotherapeutic agents in asynchronous and synchronous 9L cells. Invest New Drugs 5: 145–154, 1987

    Google Scholar 

  35. Yung WKA, Shapiro JR, Shapiro WR: Heterogeneous chemosensitivities of subpopulations of human glioma cells in culture. Cancer Res 42: 992–998, 1982

    Google Scholar 

  36. Douple EB, Richmond RC, Logan ME: Therapeutic potentiation in a mouse mammary tumor and an intracerebral rat brain tumor by combined treatment with cis-dichloro-diammineplatinum II and radiation. J Hematol Oncol 7: 585–603, 1977

    Google Scholar 

  37. Penn RD, Kroin JS, Chin KM, Braun DP: Chronic intratumoral chemotherapy of a rat tumor with cisplatin and fluorouracil. App Neurophysiol 46: 240–244, 1983

    Google Scholar 

  38. Stewart DJ, Wallace S, Feun L, Leavens M, Young SE, Handel S, Mavligit G, Benjamin RS: A phase I study of intracarotid artery infusion of cis-Diamminedichloroplatinum (II) in patients with recurrent malignant intracerebral tumors. Cancer Res 42: 2059–2062, 1982

    Google Scholar 

  39. Deconti RC, Taftness BR, Large RC, Creasey WA: Clinical and pharmacological studies with cis-diamminedichloroplatinum (II). Cancer Res 33: 1310–1315, 1973

    Google Scholar 

  40. Rall DP, Zubrod CG: Mechanisms of drug absorption and excretion; passage of drugs in and out of the central nervous system. Ann Rev Pharmacol 2: 109–128, 1962

    Google Scholar 

  41. Hanka LJ, Martin DG, Neil GL: A new antitumor anti-metabolite, (aS,5S)-a-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid (NSC 163501): antimicrobial reversal studies and preliminary evaluation against L1210 leukemia in vivo. Cancer Chemother Rep 57: 141–148, 1973

    Google Scholar 

  42. Jayaram HN, Cooney DA, Ryan JA, Neil GL, Dion RL, Bono VH: L-[AS,5S]-a-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid (NSC 163501): a new amino acid antibiotic with the properties of an antagonist of L-glutamine. Cancer Chemother Rep 59: 481–491, 1975

    Google Scholar 

  43. Kensler TW, Jayaram HN, Cooney DA: Effects of acivicin and PALA, single and in combination, on de novo pyrimidine biosynthesis. Adv Enzyme Regul 20: 57–73, 1982

    Google Scholar 

  44. Houchens DP, Ovejera AA, Sheridan MA, Johnson RK, Bogden AE, Neil GL: Therapy for mouse tumors and human tumor xenografts with the antitumor antibiotic AT-125. Cancer Treat Rep 63: 473–476, 1979

    Google Scholar 

  45. Taylor SA, Belt RJ, Joseph U, Haas CD, Hoogstraten B: Phase I evaluation of AT-125 single dose every three weeks. Invest New Drugs 2: 311–314, 1984

    Google Scholar 

  46. Maroun JA, Maksymiuk A, Eisenhauer E, Stewart DJ, Young V, Pater J: Phase II study of acivicin in non-small cell lung cancer: a National Cancer Institute of Canada study. Cancer Treat Rep 70: 1327–1328, 1986

    Google Scholar 

  47. Chance WT, Cao L, Fischer JE: Prolonged survival by tumor-bearing rats treated with acivicin and total parenteral nutrition. J Natl Cancer Inst 82: 432–434, 1990

    Google Scholar 

  48. McGovern JP, Stewart JC, Elfring GL, Smith RB, Soares N, Wood JH, Poplack DG, Von Hoff DD: Plasma and cerebrospinal fluid pharmacokinetics of Acivicin in Om maya reservoir-bearing rhesus monkeys. Cancer Treat Rep 66: 1333–1341, 1982

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, University of Kansas Medical Center, 66160, Kansas City, KS

    Bruce F. Kimler, Changnian Liu & Richard G. Evans

  2. Brain Tumor Institute, 63150, Kansas City, MO, USA

    Robert A. Morantz

Authors
  1. Bruce F. Kimler
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Changnian Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Richard G. Evans
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Robert A. Morantz
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kimler, B.F., Liu, C., Evans, R.G. et al. Intracerebral chemotherapy in the 9L rat brain tumor model. J Neuro-Oncol 14, 191–200 (1992). https://doi.org/10.1007/BF00172594

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00172594

Key words

Search

Navigation